Cargando…

HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data

BACKGROUND: Mantle Cell Lymphoma (MCL) is a B cell aggressive neoplasia accounting for about the 6% of all lymphomas. The most common molecular marker of clonality in MCL, as in other B lymphoproliferative disorders, is the ImmunoGlobulin Heavy chain (IGH) rearrangement, occurring in B-lymphocytes....

Descripción completa

Detalles Bibliográficos
Autores principales: Beccuti, Marco, Genuardi, Elisa, Romano, Greta, Monitillo, Luigia, Barbero, Daniela, Boccadoro, Mario, Ladetto, Marco, Calogero, Raffaele, Ferrero, Simone, Cordero, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701356/
https://www.ncbi.nlm.nih.gov/pubmed/29169317
http://dx.doi.org/10.1186/s12859-017-1923-2
_version_ 1783281319652884480
author Beccuti, Marco
Genuardi, Elisa
Romano, Greta
Monitillo, Luigia
Barbero, Daniela
Boccadoro, Mario
Ladetto, Marco
Calogero, Raffaele
Ferrero, Simone
Cordero, Francesca
author_facet Beccuti, Marco
Genuardi, Elisa
Romano, Greta
Monitillo, Luigia
Barbero, Daniela
Boccadoro, Mario
Ladetto, Marco
Calogero, Raffaele
Ferrero, Simone
Cordero, Francesca
author_sort Beccuti, Marco
collection PubMed
description BACKGROUND: Mantle Cell Lymphoma (MCL) is a B cell aggressive neoplasia accounting for about the 6% of all lymphomas. The most common molecular marker of clonality in MCL, as in other B lymphoproliferative disorders, is the ImmunoGlobulin Heavy chain (IGH) rearrangement, occurring in B-lymphocytes. The patient-specific IGH rearrangement is extensively used to monitor the Minimal Residual Disease (MRD) after treatment through the standardized Allele-Specific Oligonucleotides Quantitative Polymerase Chain Reaction based technique. Recently, several studies have suggested that the IGH monitoring through deep sequencing techniques can produce not only comparable results to Polymerase Chain Reaction-based methods, but also might overcome the classical technique in terms of feasibility and sensitivity. However, no standard bioinformatics tool is available at the moment for data analysis in this context. RESULTS: In this paper we present HashClone, an easy-to-use and reliable bioinformatics tool that provides B-cells clonality assessment and MRD monitoring over time analyzing data from Next-Generation Sequencing (NGS) technique. The HashClone strategy-based is composed of three steps: the first and second steps implement an alignment-free prediction method that identifies a set of putative clones belonging to the repertoire of the patient under study. In the third step the IGH variable region, diversity region, and joining region identification is obtained by the alignment of rearrangements with respect to the international ImMunoGenetics information system database. Moreover, a provided graphical user interface for HashClone execution and clonality visualization over time facilitate the tool use and the results interpretation. The HashClone performance was tested on the NGS data derived from MCL patients to assess the major B-cell clone in the diagnostic samples and to monitor the MRD in the real and artificial follow up samples. CONCLUSIONS: Our experiments show that in all the experimental settings, HashClone was able to correctly detect the major B-cell clones and to precisely follow them in several samples showing better accuracy than the state-of-art tool. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12859-017-1923-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5701356
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57013562017-12-01 HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data Beccuti, Marco Genuardi, Elisa Romano, Greta Monitillo, Luigia Barbero, Daniela Boccadoro, Mario Ladetto, Marco Calogero, Raffaele Ferrero, Simone Cordero, Francesca BMC Bioinformatics Research Article BACKGROUND: Mantle Cell Lymphoma (MCL) is a B cell aggressive neoplasia accounting for about the 6% of all lymphomas. The most common molecular marker of clonality in MCL, as in other B lymphoproliferative disorders, is the ImmunoGlobulin Heavy chain (IGH) rearrangement, occurring in B-lymphocytes. The patient-specific IGH rearrangement is extensively used to monitor the Minimal Residual Disease (MRD) after treatment through the standardized Allele-Specific Oligonucleotides Quantitative Polymerase Chain Reaction based technique. Recently, several studies have suggested that the IGH monitoring through deep sequencing techniques can produce not only comparable results to Polymerase Chain Reaction-based methods, but also might overcome the classical technique in terms of feasibility and sensitivity. However, no standard bioinformatics tool is available at the moment for data analysis in this context. RESULTS: In this paper we present HashClone, an easy-to-use and reliable bioinformatics tool that provides B-cells clonality assessment and MRD monitoring over time analyzing data from Next-Generation Sequencing (NGS) technique. The HashClone strategy-based is composed of three steps: the first and second steps implement an alignment-free prediction method that identifies a set of putative clones belonging to the repertoire of the patient under study. In the third step the IGH variable region, diversity region, and joining region identification is obtained by the alignment of rearrangements with respect to the international ImMunoGenetics information system database. Moreover, a provided graphical user interface for HashClone execution and clonality visualization over time facilitate the tool use and the results interpretation. The HashClone performance was tested on the NGS data derived from MCL patients to assess the major B-cell clone in the diagnostic samples and to monitor the MRD in the real and artificial follow up samples. CONCLUSIONS: Our experiments show that in all the experimental settings, HashClone was able to correctly detect the major B-cell clones and to precisely follow them in several samples showing better accuracy than the state-of-art tool. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12859-017-1923-2) contains supplementary material, which is available to authorized users. BioMed Central 2017-11-23 /pmc/articles/PMC5701356/ /pubmed/29169317 http://dx.doi.org/10.1186/s12859-017-1923-2 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Beccuti, Marco
Genuardi, Elisa
Romano, Greta
Monitillo, Luigia
Barbero, Daniela
Boccadoro, Mario
Ladetto, Marco
Calogero, Raffaele
Ferrero, Simone
Cordero, Francesca
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data
title HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data
title_full HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data
title_fullStr HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data
title_full_unstemmed HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data
title_short HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data
title_sort hashclone: a new tool to quantify the minimal residual disease in b-cell lymphoma from deep sequencing data
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701356/
https://www.ncbi.nlm.nih.gov/pubmed/29169317
http://dx.doi.org/10.1186/s12859-017-1923-2
work_keys_str_mv AT beccutimarco hashcloneanewtooltoquantifytheminimalresidualdiseaseinbcelllymphomafromdeepsequencingdata
AT genuardielisa hashcloneanewtooltoquantifytheminimalresidualdiseaseinbcelllymphomafromdeepsequencingdata
AT romanogreta hashcloneanewtooltoquantifytheminimalresidualdiseaseinbcelllymphomafromdeepsequencingdata
AT monitilloluigia hashcloneanewtooltoquantifytheminimalresidualdiseaseinbcelllymphomafromdeepsequencingdata
AT barberodaniela hashcloneanewtooltoquantifytheminimalresidualdiseaseinbcelllymphomafromdeepsequencingdata
AT boccadoromario hashcloneanewtooltoquantifytheminimalresidualdiseaseinbcelllymphomafromdeepsequencingdata
AT ladettomarco hashcloneanewtooltoquantifytheminimalresidualdiseaseinbcelllymphomafromdeepsequencingdata
AT calogeroraffaele hashcloneanewtooltoquantifytheminimalresidualdiseaseinbcelllymphomafromdeepsequencingdata
AT ferrerosimone hashcloneanewtooltoquantifytheminimalresidualdiseaseinbcelllymphomafromdeepsequencingdata
AT corderofrancesca hashcloneanewtooltoquantifytheminimalresidualdiseaseinbcelllymphomafromdeepsequencingdata